| (Values in U.S. Thousands) | Dec, 2018 | Dec, 2017 | Dec, 2016 | Dec, 2015 | Dec, 2014 |
| Sales | 8,730 | 11,180 | 41,770 | 26,060 | 19,970 |
| Sales Growth | -21.91% | -73.23% | +60.28% | +30.50% | +7.89% |
| Net Income | -186,510 | -125,620 | -71,230 | -27,090 | -20,180 |
| Net Income Growth | -48.47% | -76.36% | -162.94% | -34.24% | -53.93% |
Achaogen Inc (AKAOQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Achaogen Inc. is a biopharmaceutical company. It is engaged in developing and commercializing antibacterial agents to address multi-drug resistant gram-negative infections. The company's principal product is ZEMDRI, for the treatment of adults with complicated urinary tract infections, including pyelonephritis. Achaogen Inc. is based in San Francisco, United States.
Fiscal Year End Date: 12/31